Nicoletta Colombo
Overview
Explore the profile of Nicoletta Colombo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
310
Citations
11124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fumagalli D, Jayraj A, Olearo E, Capasso I, Hsu H, Tzur Y, et al.
Int J Gynecol Cancer
. 2025 Mar;
35(3):101664.
PMID: 40022844
Background: The standard treatment for advanced epithelial ovarian cancer is primary cytoreductive surgery, with the goal of achieving no residual disease. Neoadjuvant chemotherapy and interval cytoreductive surgery can be viable...
2.
Vergote I, Copeland L, Van Gorp T, Laenen A, Scambia G, Thaker P, et al.
Eur J Cancer
. 2025 Feb;
219:115306.
PMID: 40010134
Purpose: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability and tumor progression. The pivotal, phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study evaluated efficacy and safety of...
3.
Valenza C, Mongillo M, Visconti M, Katrini J, Trapani D, Boldrini L, et al.
Gynecol Oncol
. 2025 Feb;
194:11-17.
PMID: 39923679
Background: According to the 2018 ESMO-ESGO consensus conference recommendations on ovarian cancer, platinum rechallenge could be considered in patients with platinum-resistant disease following a treatment with a non‑platinum regimen, if...
4.
Oza A, Lisyanskaya A, Fedenko A, de Melo A, Shparyk Y, Rakhmatullina I, et al.
Lancet Oncol
. 2025 Feb;
26(2):249-264.
PMID: 39914419
Background: In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, showing improved investigator-assessed progression-free survival with rucaparib. Here,...
5.
De Vitis L, Schivardi G, Delfrati S, Biffi B, Viscardi A, Rosanu M, et al.
Int J Gynecol Cancer
. 2025 Jan;
35(1):100024.
PMID: 39878279
Objective: No biomarkers are available to predict treatment response in patients with endometrial cancers who undergo fertility-sparing treatment. Therefore, we aimed to evaluate the prognostic role of molecular classification. Methods:...
6.
Oaknin A, Monk B, de Melo A, Kim H, Kim Y, Lisyanskaya A, et al.
Eur J Cancer
. 2025 Jan;
216:115146.
PMID: 39798514
Aim: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the...
7.
Prato-Previde E, De Mori B, Colombo N, Pelosi A
Animals (Basel)
. 2025 Jan;
14(24.
PMID: 39765597
Veterinarians face ethical challenges during their careers, but despite evidence of work-related stress and burnout in veterinarians, moral distress has been poorly investigated. Using an online survey, professional experience, moral...
8.
Bogani G, Moore K, Ray-Coquard I, Lorusso D, Matulonis U, Ledermann J, et al.
Gynecol Oncol
. 2025 Jan;
193:30-40.
PMID: 39764856
Objective: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need...
9.
Quesada S, Penault-Llorca F, Matias-Guiu X, Banerjee S, Barberis M, Coleman R, et al.
Eur J Cancer
. 2024 Dec;
215:115169.
PMID: 39693891
Background: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency...
10.
Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath 3rd C, Bidzinski M, et al.
J Clin Oncol
. 2024 Dec;
:JCO2400933.
PMID: 39668137
Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3...